Premium – Page 2 – Endpoints News

SUBSCRIBE

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

7 months ago

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

7 months ago

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

7 months ago

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

7 months ago

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

7 months ago

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

8 months ago

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

8 months ago

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

8 months ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

8 months ago

The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry

9 months ago

Winners and losers at #ESMO18

10 months ago

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

11 months ago

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

11 months ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

11 months ago

Global reach: The top 25 biopharma companies in the world

12 months ago

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

Last year

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

Last year

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

Last year

Top 10 pipeline blowups, setbacks and snafus in H1 2018

Last year

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

Last year

12 top China VCs you need to know who are making a transpacific splash (Part 2)

Last year

RIP XTuit: Great brains, hot target and vet CEO Deborah Dunsire in charge couldn’t stop this biotech from going down

Last year

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

Last year

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

Last year

First page Previous page 123 Next page Last page